Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial

NCT ID: NCT07264686

Last Updated: 2025-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

222 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-03

Study Completion Date

2026-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Small cutaneous ulcers are common in Papua New Guinea but are normally left untreated due to lack of easy access to basic medicines. The goal of this clinical trial is to test the efficacy of a readily available antibacterial plant medicine called Pterocarpus indicus comparing healing outcomes to control arms receiving Savlon antiseptic cream and no treatment. Participants with cutaneous ulcers less than 1cm in diameter will be randomized to receive topical treatment with a plant medicines, Savlon cream or no treatment treatment and followed up at day 7 and 14 to assess ulcer healing and ulcer surface area.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Small, infected skin ulcers are very common in children living in rural areas of Papua New Guinea (PNG) and represent a large area of unmet clinical need. These painful and debilitating ulcers often occur on the lower leg area and are suspected to be associated with a range of different bacterial pathogens including Haemophilus ducreyi and Streptococcus pyogenes. Topical antiseptics such as chlorhexidine-based antiseptic creams or antibiotics such as amoxicillin may be effective treatment options, but in rural areas of PNG, infected skin ulcers are normally left untreated due to a lack of access to such treatments. The need to walk many miles to reach an aid post, often barefoot and through swampy or muddy ground, compromises the real-world effectiveness of such treatments in PNG. In this study we propose to test the effectiveness of three antibacterial traditional plant medicines, each of which has a long history of use in PNG as a plant-based topical antiseptic that is applied directly onto infected skin ulcers. The plant medicine Pterocarpus indicus is an antibacterial plant sap which as a viscous fluid can be easily applied directly onto the surface of infected ulcers. Unlike antibiotics such as amoxicillin which demand access to an aid post or clinic, this plant medicine can be easily found growing in or very near to most villages in PNG. Highly accessible, medicinal plant saps could form the basis of a cost-effective treatment option for PNG in remote areas, and may reduce the use of antibiotics. The trial proposed in this application aims to discover if such plant medicines are indeed efficacious when compared to Savlon cream or no treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous Ulcer Disease Skin Sores

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study we propose is an evaluator-blinded, randomized clinical trial to compare the effects of topical application of a traditional medicine plant sap compared to Savlon cream and no treatment:

(A) Pterocarpus indicus plant sap (50μl) applied topically at baseline and for four more days (B) Savlon cream (200mg) applied topically at baseline and for four more days (C) No treatment
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ficus septica exudate

Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).

Group Type EXPERIMENTAL

Ficus septica exudate

Intervention Type OTHER

Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).

Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)

Common over the counter antiseptic cream

Group Type ACTIVE_COMPARATOR

Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)

Intervention Type DRUG

Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)

Control

no intevention control

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ficus septica exudate

Description: P. indicus sap exhibits antibacterial activivity agaisnt S. pyogenes, a pàthogen associated with cutaneous ulcer disease in Papau New Guinea. The sap has been tested using the Ames test for mutagenesis, and found to be non-mutagenic; testing was carried out by toxicology service provider Gentronix, UK (results available separately on request).

Intervention Type OTHER

Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)

Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infected skin ulcer suspected with one or more predominantly moist ulcerative skin lesions of less than 1 cm diameter in greatest dimension and larger than 0.5cm in largest dimension with a predominantly moist surface, occurring below the knee.
* Accepted and signed informed consent by a legal guardian (relative or teacher)
* Ability and willingness to comply with the requirements of the study protocol including follow up visits.

Exclusion Criteria

* Children younger than 5 years old.
* Ulcer presenting with a crust (not predominantly moist surface), or dimensions different to those specified in point 1 above.
* Refusal at ward level or village chief (for village inclusion), or refusal of individual or guardian (for individual inclusion).
* Answered yes when asked if had taken antibiotics in the last week or presents with visible signs of ulcer treatment e.g. wound dressing.
Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Royal Botanic Gardens, Kew

UNKNOWN

Sponsor Role collaborator

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vunapope Hospital, and surrounding area

Kokopo, EAST NEW Britan, Papua New Guinea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Papua New Guinea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UlcerPlants2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acetic Acid 2% Solution for Skin Ulcers
NCT06297967 RECRUITING PHASE3
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
NCT04803708 COMPLETED PHASE1/PHASE2
Reduction of Bacteria in MRSA Positive Ulcers
NCT00771368 TERMINATED PHASE1/PHASE2
HM242-Solution vs Comparator
NCT04902612 UNKNOWN NA
Diabetic Foot Ulcer Research Study
NCT05762432 RECRUITING NA